Your browser doesn't support javascript.
loading
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Yao, Song; Laurent, Cecile A; Roh, Janise M; Lo, Joan; Tang, Li; Hahn, Theresa; Ambrosone, Christine B; Kushi, Lawrence H; Kwan, Marilyn L.
Afiliação
  • Yao S; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. song.yao@roswellpark.org.
  • Laurent CA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Roh JM; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Lo J; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Tang L; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
  • Hahn T; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Ambrosone CB; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
  • Kushi LH; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Kwan ML; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Breast Cancer Res Treat ; 180(1): 187-195, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31912328
ABSTRACT

PURPOSE:

Osteoporosis and fragility fracture are major bone toxicities of aromatase inhibitors (AIs) for postmenopausal hormone receptor-positive breast cancer. Except for a few small studies on bone turnover markers and reduced bone mineral density after AI treatment, data on the associations of bone markers and risk of osteoporosis or fracture from prospective studies are lacking.

METHODS:

In a prospective study of 1709 women on AIs, two bone turnover markers, BALP and TRACP, and two bone regulatory markers, RANKL and OPG, were measured and examined in relation to risk of osteoporosis and fragility fractures during a median follow-up time of 6.1 years.

RESULTS:

Higher levels of BALP and TRACP were both associated with increased risk of osteoporosis and higher BALP/TRACP ratios were associated with lower risk of osteoporosis, but no associations were observed for fracture risk. Higher levels of OPG were associated with increased risk of fracture, whereas higher levels of RANKL were associated with lower risk. As a result, OPG/RANKL ratios were positively associated with fracture risk [hazard ratio (HR) = 2.49, 95% confidence interval (CI) 1.34-4.61]. After controlling for age and fracture history, the associations became non-significant but a suggestive trend remained (HR = 1.80, 95% CI 0.96-3.37).

CONCLUSION:

Our study provides suggestive evidence for the potential utility of OPG/RANKL ratios in predicting risk of fracture in women treated with AIs for breast cancer. Further validation may be warranted.
Assuntos
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Osteoporose / Neoplasias da Mama / Biomarcadores / Fraturas Ósseas Tipo de estudo: Estudo diagnóstico / Estudo de etiologia / Estudo de incidência / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Inglês Revista: Breast Cancer Res Treat Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Estados Unidos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Osteoporose / Neoplasias da Mama / Biomarcadores / Fraturas Ósseas Tipo de estudo: Estudo diagnóstico / Estudo de etiologia / Estudo de incidência / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Inglês Revista: Breast Cancer Res Treat Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Estados Unidos